Roivant Sciences Ltd (ROIV) - Total Assets
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) holds total assets worth $5.23 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ROIV debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Roivant Sciences Ltd - Total Assets Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's total assets have evolved over time, based on quarterly financial data. See Roivant Sciences Ltd net assets for net asset value and shareholders' equity analysis.
Roivant Sciences Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Roivant Sciences Ltd's total assets of $5.23 Billion consist of 92.0% current assets and 8.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Roivant Sciences Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Roivant Sciences Ltd's current assets represent 92.0% of total assets in 2025, an increase from 85.4% in 2019.
- Cash Position: Cash and equivalents constituted 49.9% of total assets in 2025, down from 61.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Roivant Sciences Ltd Competitors by Total Assets
Key competitors of Roivant Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
Roivant Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 30.66 | 37.91 | 9.99 |
| Quick Ratio | 30.66 | 37.91 | 9.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.51 Billion | $5.22 Billion | $1.97 Billion |
Roivant Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Roivant Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.79 |
| Latest Market Cap to Assets Ratio | 3.76 |
| Asset Growth Rate (YoY) | -24.7% |
| Total Assets | $5.44 Billion |
| Market Capitalization | $20.44 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Roivant Sciences Ltd's assets at a significant premium (3.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Roivant Sciences Ltd's assets decreased by 24.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Roivant Sciences Ltd (2019–2025)
The table below shows the annual total assets of Roivant Sciences Ltd from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $5.44 Billion | -24.72% |
| 2024-03-31 | $7.22 Billion | +202.25% |
| 2023-03-31 | $2.39 Billion | -7.56% |
| 2022-03-31 | $2.59 Billion | -3.89% |
| 2021-03-31 | $2.69 Billion | +8.58% |
| 2020-03-31 | $2.48 Billion | +78.49% |
| 2019-03-31 | $1.39 Billion | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more